1: Kuriki A, Kumazawa T, Lee XP, Hasegawa C, Kawamura M, Suzuki O, Sato K. Simultaneous determination of selegiline and desmethylselegiline in human body fluids by headspace solid-phase microextraction and gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Dec 5;844(2):283-91. Epub 2006 Aug 7. PubMed PMID: 16893687. 2: Heinonen EH, Anttila MI, Karnani HL, Nyman LM, Vuorinen JA, Pyykkö KA, Lammintausta RA. Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans. J Clin Pharmacol. 1997 Jul;37(7):602-9. PubMed PMID: 9243353. 3: Benetton SA, Fang C, Yang YO, Alok R, Year M, Lin CC, Yeh LT. P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine. Drug Metab Pharmacokinet. 2007 Apr;22(2):78-87. PubMed PMID: 17495414. 4: Mizuta I, Ohta M, Ohta K, Nishimura M, Mizuta E, Hayashi K, Kuno S. Selegiline and desmethylselegiline stimulate NGF, BDNF, and GDNF synthesis in cultured mouse astrocytes. Biochem Biophys Res Commun. 2000 Dec 29;279(3):751-5. PubMed PMID: 11162424. 5: Takahata K, Katsuki H, Kobayashi Y, Muraoka S, Yoneda F, Kume T, Kashii S, Honda Y, Akaike A. Protective effects of selegiline and desmethylselegiline against N-methyl-D-aspartate-induced rat retinal damage. Eur J Pharmacol. 2003 Jan 1;458(1-2):81-9. PubMed PMID: 12498910. 6: Andreassen OA, Dedeoglu A, Friedlich A, Ferrante KL, Hughes D, Szabo C, Beal MF. Effects of an inhibitor of poly(ADP-ribose) polymerase, desmethylselegiline, trientine, and lipoic acid in transgenic ALS mice. Exp Neurol. 2001 Apr;168(2):419-24. PubMed PMID: 11259130. 7: Mascher HJ, Kikuta C, Millendorfer A, Schiel H, Ludwig G. Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. Int J Clin Pharmacol Ther. 1997 Jan;35(1):9-13. PubMed PMID: 9021435. 8: Slawson MH, Taccogno JL, Foltz RL, Moody DE. Quantitative analysis of selegiline and three metabolites (N-desmethylselegiline, methamphetamine, and amphetamine) in human plasma by high-performance liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. J Anal Toxicol. 2002 Oct;26(7):430-7. PubMed PMID: 12422997. 9: Mytilineou C, Radcliffe PM, Olanow CW. L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro. J Neurochem. 1997 Jan;68(1):434-6. PubMed PMID: 8978757. 10: Taavitsainen P, Anttila M, Nyman L, Karnani H, Salonen JS, Pelkonen O. Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes. Pharmacol Toxicol. 2000 May;86(5):215-21. PubMed PMID: 10862503. 11: Mytilineou C, Leonardi EK, Radcliffe P, Heinonen EH, Han SK, Werner P, Cohen G, Olanow CW. Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion. J Pharmacol Exp Ther. 1998 Feb;284(2):700-6. PubMed PMID: 9454817. 12: Kivistö KT, Wang JS, Backman JT, Nyman L, Taavitsainen P, Anttila M, Neuvonen PJ. Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole. Eur J Clin Pharmacol. 2001 Apr;57(1):37-42. PubMed PMID: 11372588. 13: Nishida K, Itoh S, Inoue N, Kudo K, Ikeda N. High-performance liquid chromatographic-mass spectrometric determination of methamphetamine and amphetamine enantiomers, desmethylselegiline and selegiline, in hair samples of long-term methamphetamine abusers or selegiline users. J Anal Toxicol. 2006 May;30(4):232-7. PubMed PMID: 16803660. 14: Kronstrand R, Ahlner J, Dizdar N, Larson G. Quantitative analysis of desmethylselegiline, methamphetamine, and amphetamine in hair and plasma from Parkinson patients on long-term selegiline medication. J Anal Toxicol. 2003 Apr;27(3):135-41. PubMed PMID: 12731653. 15: Laine K, Anttila M, Huupponen R, Mäki-Ikola O, Heinonen E. Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding. Clin Neuropharmacol. 2000 Jan-Feb;23(1):22-7. PubMed PMID: 10682227. 16: Palovaara S, Anttila M, Nyman L, Laine K. Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline. Eur J Clin Pharmacol. 2002 Jul;58(4):259-63. Epub 2002 May 22. PubMed PMID: 12136372. 17: Laine K, Anttila M, Nyman L, Wahlberg A, Bertilsson L. CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline. Eur J Clin Pharmacol. 2001 May;57(2):137-42. PubMed PMID: 11417445. 18: Barrett JS, Rohatagi S, DeWitt KE, Morales RJ, DiSanto AR. The Effect of Dosing Regimen and Food on the Bioavailability of the Extensively Metabolized, Highly Variable Drug Eldepryl(®) (Selegiline Hydrochloride). Am J Ther. 1996 Apr;3(4):298-313. PubMed PMID: 11862265. 19: Scheinin H, Anttila M, Dahl ML, Karnani H, Nyman L, Taavitsainen P, Pelkonen O, Bertilsson L. CYP2D6 polymorphism is not crucial for the disposition of selegiline. Clin Pharmacol Ther. 1998 Oct;64(4):402-11. PubMed PMID: 9797797. 20: Mahmood I, Neau SH, Mason WD. An enzymatic assay for the MAO-B inhibitor selegiline in plasma. J Pharm Biomed Anal. 1994 Jul;12(7):895-9. PubMed PMID: 7981318.